Delivery Order SPE2DB22D2206-SPE2DB24FEN75
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $30,025.41 firm fixed-price delivery order is for the supply of 4,566,133,790 units of 300 mg Rifampin capsules. The award does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $17,866.46, is a delivery order for the supply of 60 units of 300 mg Rifampin capsules. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- The U.S. Department of Defense (DoD) Defense Logistics Agency (DLA) Troop Support Medical awarded a $4,504.35 firm fixed-price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the supply of 4559012573 - Rifampin 150 mg Capsule 30s. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 2025, for the comprehensive delivery of pharmaceutical products and medical...
- This federal contract award, with ID SPE2DB22D2006|SPE2DB25FV7CD, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $31,360.66 firm fixed-price delivery order is for the supply of 60 counts of 300 mg Rifampin capsules. The contract has an ultimate completion date of December 17, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,648.47, is for the delivery of 4,567,529,290 units of Rifampin 300mg capsules. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of April 7, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,841.06 Firm Fixed Price contract is for the delivery of 60 count bottles of 300 mg rifampin capsules. The contract has a period of performance through May 29, 2025 and is not a set-aside award. Amerisourcebergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,381.11 delivery order contract is for the supply of RIFAMPIN 300 MG CAPSULE 60S, a pharmaceutical product. The contract has an ultimate completion date of January 22, 2025 and is a firm fixed price arrangement. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
- The U.S. Defense Logistics Agency (DLA) has awarded a $29,964.06 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp for the supply of 4,565,470 units of Rifampin 300 mg capsules. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between the DLA Troop Support Medical and Amerisourcebergen, valued at up to $999,999,999 through December 2025, for the provision of a comprehensive range of medical commodities to support military treatment programs and...
- This federal contract award, valued at $4,582.82, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Rifampin 300 mg capsules and does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026....
- This contract award is to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Rifampin 300 mg capsules to the Defense Logistics Agency (DLA). The award is a Firm Fixed Price Delivery Order valued at $5,850.40 and runs through September 4, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, which serves as the primary vehicle for providing...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB24FEN75Delivery Order
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., for the delivery of 60 capsules of 300 mg Rifampin. The single-award Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00, serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare programs globally. The contract, which runs through November 2026, encompasses critical medical commodities including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. This delivery order, valued at $6,398.13, is not designated with a set-aside requirement, indicating open competition. Additionally, Amerisourcebergen holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, covering similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.4k | 12/8/23 |